PubMed:19233913
Annnotations
PMID_GLOBAL
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 49-57 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T2 | 122-130 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T3 | 227-232 | DiseaseOrPhenotypicFeature | denotes | tumor | 0005070 |
| T4 | 273-281 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T5 | 551-559 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T6 | 618-626 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T7 | 720-728 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T8 | 903-911 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T9 | 1099-1107 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T10 | 1242-1250 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T11 | 1301-1304 | DiseaseOrPhenotypicFeature | denotes | can | 0012833 |
| T12 | 1328-1336 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T13 | 1560-1568 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T14 | 1639-1647 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T15 | 1751-1759 | DiseaseOrPhenotypicFeature | denotes | melanoma | 0005105 |
| T16 | 1776-1779 | DiseaseOrPhenotypicFeature | denotes | can | 0012833 |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-185 | Sentence | denotes | mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. |
| TextSentencer_T2 | 186-197 | Sentence | denotes | BACKGROUND: |
| TextSentencer_T3 | 198-395 | Sentence | denotes | The detection of circulating tumor cells (CTCs) in the peripheral blood of melanoma patients by quantitative real-time reverse-transcription PCR (qRT-PCR) analysis correlates with a poor prognosis. |
| TextSentencer_T4 | 396-566 | Sentence | denotes | The assessment of CTCs from blood has been difficult because of lack of a good monoclonal antibody (mAb) directed against surface cell antigens to capture melanoma cells. |
| TextSentencer_T5 | 567-575 | Sentence | denotes | METHODS: |
| TextSentencer_T6 | 576-697 | Sentence | denotes | Blood was collected prospectively from 57 melanoma patients (43 test and 14 test-development cases) and 5 healthy donors. |
| TextSentencer_T7 | 698-870 | Sentence | denotes | High molecular weight melanoma-associated antigen (HMW-MAA)-specific mAbs bound to immunomagnetic beads were used to isolate CTCs. mRNA and/or DNA were extracted from CTCs. |
| TextSentencer_T8 | 871-1114 | Sentence | denotes | Testing for the expression of a melanoma-associated gene panel (MLANA, MAGEA3, and MITF) with qRT-PCR and for the presence of BRAFmt (a BRAF gene variant encoding the V600E mutant protein) verified the beads-isolated CTCs to be melanoma cells. |
| TextSentencer_T9 | 1115-1186 | Sentence | denotes | A peptide nucleic acid-clamping PCR assay was used for BRAFmt analysis. |
| TextSentencer_T10 | 1187-1195 | Sentence | denotes | RESULTS: |
| TextSentencer_T11 | 1196-1488 | Sentence | denotes | Spiking of peripheral blood cells (PBCs) with melanoma cells showed that the beads-based detection assay can detect approximately 1 melanoma cell in 5 x 10(6) PBCs. qRT-PCR analysis detected MLANA, MAGEA3, and MITF expression in 19 (44%), 29 (67%), and 19 (44%) of the patients, respectively. |
| TextSentencer_T12 | 1489-1578 | Sentence | denotes | At least one biomarker of the panel was positive in 40 (93%) of the 43 melanoma patients. |
| TextSentencer_T13 | 1579-1657 | Sentence | denotes | BRAFmt was detected in 17 (81%) of the 21 assessed stage IV melanoma patients. |
| TextSentencer_T14 | 1658-1669 | Sentence | denotes | CONCLUSION: |
| TextSentencer_T15 | 1670-1848 | Sentence | denotes | The assay of bead capture coupled with the PCR has utility for assessing CTCs in melanoma patients, which can then be characterized for both genomic and transcriptome expression. |
| T1 | 0-185 | Sentence | denotes | mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. |
| T2 | 186-197 | Sentence | denotes | BACKGROUND: |
| T3 | 198-395 | Sentence | denotes | The detection of circulating tumor cells (CTCs) in the peripheral blood of melanoma patients by quantitative real-time reverse-transcription PCR (qRT-PCR) analysis correlates with a poor prognosis. |
| T4 | 396-566 | Sentence | denotes | The assessment of CTCs from blood has been difficult because of lack of a good monoclonal antibody (mAb) directed against surface cell antigens to capture melanoma cells. |
| T5 | 567-575 | Sentence | denotes | METHODS: |
| T6 | 576-697 | Sentence | denotes | Blood was collected prospectively from 57 melanoma patients (43 test and 14 test-development cases) and 5 healthy donors. |
| T7 | 698-870 | Sentence | denotes | High molecular weight melanoma-associated antigen (HMW-MAA)-specific mAbs bound to immunomagnetic beads were used to isolate CTCs. mRNA and/or DNA were extracted from CTCs. |
| T8 | 871-1114 | Sentence | denotes | Testing for the expression of a melanoma-associated gene panel (MLANA, MAGEA3, and MITF) with qRT-PCR and for the presence of BRAFmt (a BRAF gene variant encoding the V600E mutant protein) verified the beads-isolated CTCs to be melanoma cells. |
| T9 | 1115-1186 | Sentence | denotes | A peptide nucleic acid-clamping PCR assay was used for BRAFmt analysis. |
| T10 | 1187-1195 | Sentence | denotes | RESULTS: |
| T11 | 1196-1488 | Sentence | denotes | Spiking of peripheral blood cells (PBCs) with melanoma cells showed that the beads-based detection assay can detect approximately 1 melanoma cell in 5 x 10(6) PBCs. qRT-PCR analysis detected MLANA, MAGEA3, and MITF expression in 19 (44%), 29 (67%), and 19 (44%) of the patients, respectively. |
| T12 | 1489-1578 | Sentence | denotes | At least one biomarker of the panel was positive in 40 (93%) of the 43 melanoma patients. |
| T13 | 1579-1657 | Sentence | denotes | BRAFmt was detected in 17 (81%) of the 21 assessed stage IV melanoma patients. |
| T14 | 1658-1669 | Sentence | denotes | CONCLUSION: |
| T15 | 1670-1848 | Sentence | denotes | The assay of bead capture coupled with the PCR has utility for assessing CTCs in melanoma patients, which can then be characterized for both genomic and transcriptome expression. |
DisGeNET
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 942-948 | gene:4102 | denotes | MAGEA3 |
| T1 | 903-911 | disease:C0025202 | denotes | melanoma |
| T2 | 954-958 | gene:4286 | denotes | MITF |
| T3 | 903-911 | disease:C0025202 | denotes | melanoma |
| T4 | 954-958 | gene:4286 | denotes | MITF |
| T5 | 1099-1107 | disease:C0025202 | denotes | melanoma |
| T6 | 1007-1011 | gene:673 | denotes | BRAF |
| T7 | 1099-1107 | disease:C0025202 | denotes | melanoma |
| R1 | T0 | T1 | associated_with | MAGEA3,melanoma |
| R2 | T2 | T3 | associated_with | MITF,melanoma |
| R3 | T4 | T5 | associated_with | MITF,melanoma |
| R4 | T6 | T7 | associated_with | BRAF,melanoma |
DisGeNET5_variant_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 19233913-5#167#172#geners113488022 | 1038-1043 | geners113488022 | denotes | V600E |
| 19233913-5#32#40#diseaseC0025202 | 903-911 | diseaseC0025202 | denotes | melanoma |
| 19233913-5#228#236#diseaseC0025202 | 1099-1107 | diseaseC0025202 | denotes | melanoma |
| 167#172#geners11348802232#40#diseaseC0025202 | 19233913-5#167#172#geners113488022 | 19233913-5#32#40#diseaseC0025202 | associated_with | V600E,melanoma |
| 167#172#geners113488022228#236#diseaseC0025202 | 19233913-5#167#172#geners113488022 | 19233913-5#228#236#diseaseC0025202 | associated_with | V600E,melanoma |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 19233913-0#122#149#gene57730 | 122-149 | gene57730 | denotes | melanoma-associated antigen |
| 19233913-0#122#149#gene55279 | 122-149 | gene55279 | denotes | melanoma-associated antigen |
| 19233913-0#20#24#gene673 | 20-24 | gene673 | denotes | BRAF |
| 19233913-0#49#57#diseaseC0025202 | 49-57 | diseaseC0025202 | denotes | melanoma |
| 19233913-7#198#204#gene4102 | 1394-1400 | gene4102 | denotes | MAGEA3 |
| 19233913-7#210#214#gene4286 | 1406-1410 | gene4286 | denotes | MITF |
| 19233913-7#46#54#diseaseC0025202 | 1242-1250 | diseaseC0025202 | denotes | melanoma |
| 19233913-7#132#140#diseaseC0025202 | 1328-1336 | diseaseC0025202 | denotes | melanoma |
| 19233913-7#46#54#diseaseC0025202 | 1242-1250 | diseaseC0025202 | denotes | melanoma |
| 19233913-7#132#140#diseaseC0025202 | 1328-1336 | diseaseC0025202 | denotes | melanoma |
| 122#149#gene5773049#57#diseaseC0025202 | 19233913-0#122#149#gene57730 | 19233913-0#49#57#diseaseC0025202 | associated_with | melanoma-associated antigen,melanoma |
| 122#149#gene5527949#57#diseaseC0025202 | 19233913-0#122#149#gene55279 | 19233913-0#49#57#diseaseC0025202 | associated_with | melanoma-associated antigen,melanoma |
| 20#24#gene67349#57#diseaseC0025202 | 19233913-0#20#24#gene673 | 19233913-0#49#57#diseaseC0025202 | associated_with | BRAF,melanoma |
| 198#204#gene410246#54#diseaseC0025202 | 19233913-7#198#204#gene4102 | 19233913-7#46#54#diseaseC0025202 | associated_with | MAGEA3,melanoma |
| 198#204#gene4102132#140#diseaseC0025202 | 19233913-7#198#204#gene4102 | 19233913-7#132#140#diseaseC0025202 | associated_with | MAGEA3,melanoma |
| 198#204#gene410246#54#diseaseC0025202 | 19233913-7#198#204#gene4102 | 19233913-7#46#54#diseaseC0025202 | associated_with | MAGEA3,melanoma |
| 198#204#gene4102132#140#diseaseC0025202 | 19233913-7#198#204#gene4102 | 19233913-7#132#140#diseaseC0025202 | associated_with | MAGEA3,melanoma |
| 210#214#gene428646#54#diseaseC0025202 | 19233913-7#210#214#gene4286 | 19233913-7#46#54#diseaseC0025202 | associated_with | MITF,melanoma |
| 210#214#gene4286132#140#diseaseC0025202 | 19233913-7#210#214#gene4286 | 19233913-7#132#140#diseaseC0025202 | associated_with | MITF,melanoma |
| 210#214#gene428646#54#diseaseC0025202 | 19233913-7#210#214#gene4286 | 19233913-7#46#54#diseaseC0025202 | associated_with | MITF,melanoma |
| 210#214#gene4286132#140#diseaseC0025202 | 19233913-7#210#214#gene4286 | 19233913-7#132#140#diseaseC0025202 | associated_with | MITF,melanoma |
DisGeNet-2017-sample
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1454 | 122-149 | gene:57730 | denotes | melanoma-associated antigen |
| T1455 | 49-57 | disease:C0025202 | denotes | melanoma |
| R1 | T1454 | T1455 | associated_with | melanoma-associated antigen,melanoma |
| R2 | T1454 | T1455 | associated_with | melanoma-associated antigen,melanoma |
UBERON-AE
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-UBERON-AE-B_T1 | 89-94 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| PD-UBERON-AE-B_T2 | 264-269 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| PD-UBERON-AE-B_T3 | 424-429 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| PD-UBERON-AE-B_T4 | 1218-1223 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
performance-test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-UBERON-AE-B_T1 | 89-94 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| PD-UBERON-AE-B_T2 | 264-269 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| PD-UBERON-AE-B_T3 | 424-429 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| PD-UBERON-AE-B_T4 | 576-581 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | Blood |
| PD-UBERON-AE-B_T5 | 1218-1223 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |